Business Context and Reporting Period
Sunshine Biopharma Inc. filed this Form 8-K on March 10, 2022, reporting the entry into a Material Definitive Agreement for a private placement of equity securities. The transaction closed on March 14, 2022.
Key Financial Metrics
- Gross Proceeds: Approximately $8 million before transaction expenses.
- Securities Issued: 2,301,353 shares of Common Stock and 1,302,251 Pre-Funded Warrants.
- Offering Prices: $2.22 per share (Common Stock + Investor Warrant) and $2.219 per unit (Pre-Funded Warrant + Investor Warrant).
- Transaction Costs: Placement agent fees totaled 12% of gross proceeds (10% commission + 2% expense allowance) plus $100,000 in fixed fees and expenses.
- Use of Proceeds: General corporate purposes.
Material Changes and Terms
The private placement resulted in the adjustment of the exercise price for 3,764,706 existing tradeable warrants (SBFMW) to $2.22 per share, effective March 14, 2022. New Investor Warrants were issued with an exercise price of $2.22, exercisable immediately, and expiring five years from issuance. These warrants include a subsequent equity sales adjustment provision and a "floor" provision preventing the issuance of common stock equivalents below $2.00 per share without 70% holder consent while more than 50% of warrants remain outstanding.
Outlook, Risks, and Contingencies
- Registration Rights: The Company must file a resale registration statement within 15 days of its 2021 annual report or 30 days of the signing date, whichever is earlier. Failure to file or maintain effectiveness triggers liquidated damages.
- Lock-Up Period: Directors and executive officers are restricted from selling or disposing of Company securities for 90 days after the registration statement becomes effective.
- Exemption: The issuance relied on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 12% placement agent fees and the $100,000 fixed fee.
- Confirm the filing date and effectiveness status of the resale registration statement to assess potential liquidated damages risk.
- Review the impact of the $2.00 issuance floor on future capital raising flexibility.
- Monitor the exercise activity of the 3,764,706 tradeable warrants now adjusted to the $2.22 strike price.